Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Taysha Gene Therapies, Inc. | tsha-ex322_7.htm |
| EX-32.1 - EX-32.1 - Taysha Gene Therapies, Inc. | tsha-ex321_6.htm |
| EX-31.2 - EX-31.2 - Taysha Gene Therapies, Inc. | tsha-ex312_8.htm |
| EX-31.1 - EX-31.1 - Taysha Gene Therapies, Inc. | tsha-ex311_9.htm |
| EX-10.15 - EX-10.15 - Taysha Gene Therapies, Inc. | tsha-ex1015_1051.htm |
| EX-10.14 - EX-10.14 - Taysha Gene Therapies, Inc. | tsha-ex1014_852.htm |
| EX-10.13 - EX-10.13 - Taysha Gene Therapies, Inc. | tsha-ex1013_851.htm |
| EX-10.5 - EX-10.5 - Taysha Gene Therapies, Inc. | tsha-ex105_792.htm |
| EX-4.2 - EX-4.2 - Taysha Gene Therapies, Inc. | tsha-ex42_791.htm |
| 10-K - 10-K - Taysha Gene Therapies, Inc. | tsha-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-249130 on Form S-8 of our report dated March 3, 2021, relating to the financial statements of Taysha Gene Therapies, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ DELOITTE & TOUCHE LLP
Dallas, Texas
March 3, 2021